Status:

COMPLETED

Intestinal Barrier Function and Probiotics.

Lead Sponsor:

TNO

Collaborating Sponsors:

VSL Pharmaceuticals

NIZO Food Research

Conditions:

Intestinal Permeability

Challenge Test

Eligibility:

MALE

21-40 years

Phase:

NA

Brief Summary

Rationale: Enterotoxigenic Escherichia coli (ETEC) bacteria adhere to the mucosa of the proximal intestines. There it produces an toxin which presents a local and relevant challenge to the intestines....

Detailed Description

Study population: 36 Healthy male volunteers; age \>= 21 and \<= 40 years. Intervention: One group receives twice daily two sachets containing 450 billion live freeze-dried lactic acid bacteria per sa...

Eligibility Criteria

Inclusion

  • Healthy as assessed by the
  • health and lifestyle questionnaire, (P9067 F02; in Dutch)
  • physical examination
  • results of the pre-study laboratory tests
  • Males, Age \>= 21 and \<= 40 years at Day 01 of the study
  • Body Mass Index (BMI) \>= 20 and \< 33 kg/m2. Preferably in high and low body fat mass ranges as to be determined by waist circumference
  • Normal Dutch eating habits as assessed by P9067 F02
  • Voluntary participation
  • Having given written informed consent
  • Willing to comply with the study procedures, including the ETEC challenge
  • Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years
  • Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned.

Exclusion

  • Subjects with one or more of the following characteristics will be excluded from participation:
  • Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study
  • Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances
  • Having a history of medical or surgical events that may significantly affect the study outcome, including gastrointestinal illness or surgical operations,
  • Use of antibiotics, immunosuppressive drugs, antacids, laxatives or anti-diarrhoeal drugs in the last 3 months before the study
  • Alcohol consumption \> 28 units/week for males
  • Reported unexplained weight loss or gain of \> 2 kg in the month prior to the pre-study screening
  • Reported slimming or medically prescribed diet
  • Reported vegan, vegetarian or macrobiotic
  • Not willing to be off working as a food handler, in child care or as a healthcare worker with direct patient contact during the week of ETEC contamination
  • Not willing to give up blood donation during the study.
  • Personnel of TNO Quality of Life, their partner and their first and second degree relatives
  • Not having a general practitioner
  • Not willing to accept information-transfer concerning participation in the study, or information regarding his/her health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner.

Key Trial Info

Start Date :

October 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2010

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT01241201

Start Date

October 1 2010

End Date

December 1 2010

Last Update

July 21 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

TNO Quality of Life

Zeist, Utrecht, Netherlands, 3704HE